NewAmsterdam Pharma Company N.V. (NAMSW) Stock Overview
Explore NewAmsterdam Pharma Company N.V.’s financial performance, market position, analyst ratings, and future outlook.
NewAmsterdam Pharma Company N.V. (NAMSW)
Key Financials
Key Financials
Market Cap
3.6B
P/E Ratio
-16.71
EPS (TTM)
$-1.81
ROE
-0.30%
NAMSW Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, NewAmsterdam Pharma Company N.V.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of NAMSW on the NASDAQ shows an RSI of 40.89, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $29.44 for the NASDAQ listing.
Key metrics behind NewAmsterdam Pharma Company N.V.'s NASDAQ-traded stock include a P/E ratio of -16.71 and a market capitalization of 3.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of NAMSW on the NASDAQ.